Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Bioavailability Study Between Etoricoxib/Betamethasone Tablets 90 mg/0,25 mg From Laboratorios Silanes, SA de CV vs Etoricoxib Tablets 90 mg (Arcoxia®) and Betamethasone Solution 50 mg/100 mL (Celestone® Pediatric) From Laboratorios Schering-Plough SA de CV, Administered Individually or in Combination, in an Open-label, Randomized, Single-dose, 3-period, 6-sequence, 3-treatment Design in Healthy Subjects of Both Genders Under Fasting Conditions

NCT07454369 is registered in ClinicalTrials.gov with Laboratorios Silanes S.A. de C.V. as lead sponsor.

NCT NCT07454369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07454369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Bioavailability Study Between Etoricoxib/Betamethasone Tablets 90 mg/0,25 mg From Laboratorios Silanes, SA de CV vs Etoricoxib Tablets 90 mg (Arcoxia®) and Betamethasone Solution 50 mg/100 mL (Celestone® Pediatric) From Laboratorios Schering-Plough SA de CV, Administered Individually or in Combination, in an Open-label, Randomized, Single-dose, 3-period, 6-sequence, 3-treatment Design in Healthy Subjects of Both Genders Under Fasting Conditions
Lead sponsor
Laboratorios Silanes S.A. de C.V.
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2022
Completion date
January 6, 2023
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy